Burroughs Wellcome licenses Navelbine
Executive Summary
The semi-synthetic vinca alkaloid vinorelbine from the French firm Pierre Fabre Medicament will be marketed in the U.S. and Canada by B-W under the agreement. The anticancer drug "has shown activity in non-small cell lung cancer and breast cancer in Phase II trials in Europe," the firm said. B-W expects to begin clinicals for lung and breast cancer in early 1990. Fabre has obtained in return certain rights to a future anticancer compound from Wellcome in Europe.